MCHR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2758259	0.51	12/20
SCHEMBL2758228	0.61	11/20
SCHEMBL2758250	0.60	11/20
SCHEMBL2758236	0.58	11/20
SCHEMBL2758269	0.57	11/20
SCHEMBL2758238	0.57	11/20
SCHEMBL2758225	0.56	11/20
SCHEMBL2758255	0.53	11/20
SCHEMBL2758252	0.50	11/20
SCHEMBL367622	0.79	10/20
SCHEMBL2758239	0.59	10/20
SCHEMBL4355180	0.58	10/20
SCHEMBL2758231	0.58	10/20
SCHEMBL2758244	0.57	10/20
SCHEMBL2758263	0.57	10/20
SCHEMBL3545455	0.56	10/20
SCHEMBL2758232	0.56	10/20
SCHEMBL2758256	0.54	10/20
SCHEMBL2758104	0.52	10/20
SCHEMBL2758234	0.52	10/20

Clinical trials — most relevant to MCHR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia	PHASE4	UNKNOWN
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia	PHASE3	COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome	PHASE2	COMPLETED
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity	PHASE2	COMPLETED
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers	PHASE2	COMPLETED
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity	PHASE2	COMPLETED
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Postoperative Cognitive Dysfunction in Elderly and it's Relation With Sleep Disorders and Melanin Concentrating Hormone	nan	NOT_YET_RECRUITING
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment	nan	RECRUITING
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes	nan	UNKNOWN
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
Melatonin Receptor Agonist and Peripheral Biological Markers	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Effect of Preoperative Melatonin on Quality of Recovery After Elective Laparoscopic Cholecystectomy	nan	NOT_YET_RECRUITING
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa	nan	COMPLETED
Efficacy of the Administration of Melatonin 5mg in the Prevention of Delirium in Older Adults Hospitalized in the Emergency Department	nan	UNKNOWN
Glucose Tolerance, Meal Timing and MTNR1B	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MCHR2 binder may also engage these)

Protein	Name	Similarity
Q8SQ54	—	1.000	Q8SQ54 →
Q8MJ88	—	0.998	Q8MJ88 →
Q8MJ89	—	0.990	Q8MJ89 →
Q8JZL2	—	0.989	Q8JZL2 →
P35374	—	0.987	P35374 →
Q9MZ01	—	0.987	Q9MZ01 →
MCHR1	Melanin-concentrating hormone receptor 1	0.986	landscape →
P97639	—	0.986	P97639 →
Q5IJ49	—	0.985	Q5IJ49 →
Q9Z0Z6	—	0.983	Q9Z0Z6 →
F1R332	—	0.982	F1R332 →
O18982	—	0.982	O18982 →
P79785	—	0.981	P79785 →
P34976	—	0.981	P34976 →
P35373	—	0.981	P35373 →
P32303	—	0.981	P32303 →
P49685	—	0.981	P49685 →
O97663	—	0.980	O97663 →
D4A7K7	—	0.980	D4A7K7 →
P29089	—	0.980	P29089 →
E7F7V7	—	0.980	E7F7V7 →
P29754	—	0.980	P29754 →
Q28929	—	0.979	Q28929 →
P35351	—	0.979	P35351 →
P56482	—	0.978	P56482 →
P56412	—	0.978	P56412 →
Q61038	—	0.977	Q61038 →
P56491	—	0.977	P56491 →
P51676	—	0.977	P51676 →
O19024	—	0.976	O19024 →